

Annual DPhG - Meeting 2021

Deutsche Pharmazeutische Gesellschaft

VIRTUALMEETING

from 29 September – 01 October 2021

Wednesday, 29 September 2021

13:00	OPENING CEREMONY President: Dagmar Fischer Conference chair: Michaela Schulz-Siegmund (Lecture Room 1)	
13:45 - 14:30	Plenary lecture: Deep Learning and Artificial Intelligence in Pharmaceutical Research and Development Jens Meiler, Leipzig (Lecture Room 1)	
14:40- 17:45	Session 1 (Lecture Room 1)	Session 2 (Lecture Room 2)
14:40-15:40	Structural Dynamics of GPCRs informs Drug Discovery Chairs: Jens Meiler, Annette Beck-Sickinger	Unexpected Pharmaceutical Impurities – Nitrosamines and more Chairs: Maria Kristina Parr, Ulrike Holzgrabe
14:40 – 14:58	Annette Beck-Sickinger, Targeted Therapy by Peptide-Drug Conjugates Activating GPCRs	(14:40 – 15:04) Ulrike Holzgrabe, Lessons learnt from the Nitrosamine Case?
14:58 - 15:16	Christa Müller, Tools for modulating heterotrimeric G proteins	(15:04 – 15:28) Felix Bredendiek, Unexpected = Untargeted? High-resolution

15:16 – 15:28	Marcel Bermudez, A dynamic view on receptor-ligand interactions	mass spectrometry as a promising tool for structure elucidation of unknown API impurities
15:28 – 15:40	Max Keller, Hexapeptides as neuropeptide Y Y4 receptor ligands: cyclization results in increased potency and incorporation of Trp in position 4 turns agonism into antagonism	Helga Stopper, Studies on mechanism of genotoxicity of selected pyrrolizidine alkaloids in HepG2 cells
15:50-16:50	Artificial Intelligence Chairs: Thomas Efferth, Jens Meiler	Quality assurance for extemporaneous products Chairs: Dagmar Fischer, Peter Langguth
15:50 – 16:08	Daniel Merk, De novo molecular design of nuclear receptor ligands with artificial intelligence	(15:50 – 16:10) Melanie Sigg and <u>Rolf Daniels</u> , Impact of Alkanediols as Alternative Preservatives on the Galenical and Biopharmaceutical Properties of Extemporaneous Semisolid Preparations
16:08 – 16.26	Holger Gohlke, Towards predicting super-tertiary and quaternary structure of proteins and protein complexes in cells	(16:10 – 16:30) Andreas Ziegler, Plausibility Check of Pediatric Formulations in Pharmaceutical Compounding
16:26 -16:38	Oliver Koch, Neural fingerprints: How to teach a fingerprint domain-specific structural features to enhance virtual screening.	
16:38 16:50	Clara Schoeder, Structure-based immunogen design to target Ebola and Marburg virus glycoprotein broadly neutralizing antibody epitopes	(16:30 – 16:50) Anna-Maria Ciciliani, Which didactic means during pharmaceutical practical training could help to improve the quality of extemporaneous products?
17:00 - 17:45	Poster session 1 (Poster Room A)	Poster session 2 (Poster Room B)
19:00 - 20:00	Fachgruppenmeetings	

Thursday, 30 September 2021

09:00 - 09:45	Plenary lecture: How to rapidly move cell-based therapies from bench to bedside? Ulrike Köhl (Lecture Room 1)		
9:55-12:50	Session 3 (Lecture Room 1)	9:55-13:30	Session 4 (Lecture Room 2)
9:55-10:55	Cell based Therapie Chairs: Ulrike Köhl, Uwe Platzbecker	9:55 – 10:25	Chairs: Maria Kristina Parr, Ulrike Holzgrabe Professor Shigeki Sasaki, President of Pharmaceutical Society of Japan (PSJ) Non-natural nucleic acids for biological and therapeutic tools
09:55 - 10:17	Uwe Platzbecker, Incidents and management of CAR-T Cell mediated complications	10:25 – 11:25	Bioanalytical Massspectrometry Chairs: Maria Kristina Parr, Ulrike Holzgrabe
10:17 – 10:40	Marco Herling, Clinical guidelines and outcome of CAR-T Cell Therapy in Lymphoma	10:25 – 10:43	Uta Ceglarek, Quantitative mass spectrometry in the clinical routine laboratory- where we are and where we want to go
10:40 – 10:55	Maximilian Merz, Clinical guidelines and outcome of CAR-T Cell Therapy in Myeloma	10:43 – 11:01	Kevin Pagel, Sugars in the Gas Phase – Novel Techniques to Unravel the Glycocode
		11:01 – 11:13	Maximilian Stapf, Studying ampicillin/sulbactam levels in human plasma and jaw bone tissue in patients with osteonecrosis of the jaw: Patient-related applications
		11:13 – 11:25	Kristina Dittrich, Untargeted Data-independent Lipidomics of Platelets in Cardiovascular Disease

11:05-12:05	Microbiom Chairs: Susanne Alban, Thomas Bosch		11:35-12:35	Probes for Imaging (PET-Tracer, Fluorescence-Probes) Chairs: Gerald Reischl, Tobias Ross
11:05 – 11:29	Thomas Bosch, Hygiene measures in the context of the microbiome		11:35 – 11:53	Rares Moldovan, Development and preliminary evaluation of [18F]JHU94620-d8 for PET imaging of cannabinoid receptors type 2
11:29 - 11:53	Matthias Laudes, Role of the gut microbiome in metabolic diseases		11:53 – 12:11	Gregory Bowden, Design of Experiments (DoE): A Powerful Tool for Accelerating Radiochemistry and Radiotracer Development
			12:11 – 12:23	Oliver Thorn-Seshold, Redox-activated enzyme-selective small molecule probes and prodrugs: novel tools to image and to harness the activity of thioredoxin (Trx) and thioredoxin reductase (TrxR)
11:53 – 12:05	Olaf Kelber, Gut microbiota and phytochemical constituents of natural products - pharmacological and metabolomic approaches		12:23 -12:35	Karin Bartel, Two pore channel 2 – A promising anti-cancer target can be addressed by synthetically accessible benzyltetrahydroisoquinolines
12:05 - 12:50	Poster session 3 (Poster Room B)		12:45 - 13:30	Poster session 4 (Poster Room B)
12:05 - 12:50	PubPharm Stefan Wulle, Christina Draheim, Hermann Kroll (Lecture Room 1)	Insights into Rigaku Europe SE Agnieszka Szalimov (At the Rigaku booth in the lobby area)	12:55 - 13:30	Chairs: Maria Kristina Parr, Ulrike Holzgrabe Professor Yuji Mori, Chair of the 142nd Annual Meeting of PSJ, Total Synthesis of the Red Tide Toxin Gymnocin-A and Introduction to the 142nd Annual Meeting of PSJ (Lecture Room 2)

13:45 - 14:30	Plenary lecture: Regional therapeutics for treating the disease site Avi Domb (Lecture Room 1)	
14:40-17:45	Session 5 (Lecture Room 1)	Session 6 (Lecture Room 2)
14:40-15:40	RNA Therapeutics: Drugs and their delivery Chairs: Achim Aigner, Olivia Merkel	Modulating Protein-Protein Interactions for targeted therapies Chairs: Joachim Jose, Holger Gohlke
14:40 – 14:58	Patrick Baumhof, CureVac, mRNA based Therapeutics	Johannes Koeberling, Bayer AG: First disclosure of the Plasminogen Inhibitor BAY 1453096, insights into its binding mode
14:58 – 15:16	Carsten Rudolph, ethris, Development of mRNA therapeutics for the treatment of inherited and acquired lung diseases	Christian Ottmann, Technische Universiteit Eindhoven, Molecular Glues to stabilize 14-3-3 Protein-Protein Interactions
15:16 – 15:28	Ulrich Lächelt, Folate-targeted Cas9/sgRNA ribonucleoprotein formulations for receptor-specific gene disruption in cancer cells	Eugen Proschak, Demonstrating Ligandability of the LC3A and LC3B Adapter Interface (No. 141)
15:28 – 15:40	Hannes Borchardt, Affecting the cell cycle progression, autophagy and apoptosis of pancreatic cancer cells by miRNA-506 replacement in vitro and in vivo	Sanil Bhatia, Development of first-in-class small-molecule C-terminal HSP90 inhibitors to target BCR-ABL1+ leukemia (No.155)
15:50-16:50	Nanocarriers for drug delivery: strategies, results and future directions Chairs: Karsten Mäder, Christian Wölk	Targeted Protein Degradation Chairs: Michael Gütschow, Finn Hansen
15:50 – 16:08	Twan Lammers, Smart Cancer Nanomedicine	(15:50 – 16:15) Christian Steinebach, Development of PROTAC Tools to Study Cancer Cell Biology
16:08 – 16:26	Klaus-Michael Weltring, Technology Driven Vision of Future Healthcare	
16:26 – 16:38	Claudia Jessen-Trefzer (Freiburg), Encapsulins as prodrug activating nanoreactors	(16:15 – 16:35) Matthias Schiedel, Sirt2-targeted PROTACs as molecular tools to study Sirt2 biology and mechanisms of targeted protein degradation
16:38 – 16:50	Angelika Wünsch (Münster), Nanoparticles inspired by lipoproteins: A lecithin stabilized and ApoE	

	functionalized carrier system to overcome the blood-brain barrier	
17:00 - 17:45	Poster session 5 (Poster Room C)	Poster session 6 (Poster Room A)
18:00	Vollversammlung	

20:00	Gesellschaftsabend
--------------	---------------------------

Friday, 01 October 2021

09:00 - 09:45	<p align="center">Plenary lecture: Personalised therapeutics, a new era in clinical pharmacy?</p> <p align="center">Henk-Jan Guchelaar</p> <p align="center">(Lecture Room 1)</p>	
9:55-14:10	<p>Session 7</p> <p>(Lecture Room 1)</p>	<p>Session 8</p> <p>(Lecture Room 2)</p>
9:55-10:55	<p>Translational DDI Assessment</p> <p>Chairs: Thorsten Lehr, Sebastian Wicha</p>	<p>3-D Printing in Pharmaceutics</p> <p>Chairs: Dagmar Fischer, Michael Hacker</p>
9:55 -10:13	Christoph Ritter, Risk assessment of herb-drug interactions	Julian Quodbach, Pharmaceutical 3D Printing – How additive manufacturing can change healthcare
10:13 -10:31	Robin Michelet, The use of translational modelling and simulation to assess immunomodulator–drug Interactions: lessons learned and way forward	Achim Schneeberger, 3D screen printing of oral pharmaceutical dosage forms
10:31- 10:43	Ronja Woltersdorf, Management of drug-drug interactions in German community pharmacies - practical insights	Julius Krause, 3D Printing of Mini Tablets for Pediatric Use
10:43 – 10:55	Oliver Scherf-Clavel, A PBPK model for Cabozantinib: Predicting oral anti-cancer drugs	Matthias Beudert, 3D printable poly(2-oxazoline) hydrogels for bioresponsive release of insulin-like growth factor I

11:05-12:05	Session Pediatrics - from epidemiological considerations to the individualisation of pharmacotherapy Chairs: Thilo Bertsche, Georg Hempel	11:05-12:05	Highlight Session I Chairs: Stefan Laufer, Bernhard Wunsch
11:05 – 11:23	Martina P. Neining, Patient safety in pediatric pharmacy - from drug prescription to administration	11:05 – 11:20	Max Crüsemann, Biosynthetic studies on the selective Gq signaling inhibitor FR900359
11:23 - 11:41	Stephanie Läer, Challenges and solutions of pediatric pharmacotherapy - off-label is not off knowledge	11:20 – 11:35	Matthias Gehringer, Development of the First Targeted Covalent Inhibitor of Monopolar Spindle Kinase 1
11:41 -11:53	Sven Jirschitzka, Compatibility study of ethacrynic acid with common drugs in paediatric-cardiological intensive care	11:35 – 11:50	Thanigaimalai Pillaiyar, Design, synthesis and biological evaluation of SARS-CoV-2 Main Protease Inhibitors
11:53 -12:05	Markus Herzig, Use of pharmaceutical products by children and adolescents - A pharmacoepidemiological evaluation of the LIFE Child study	11:50 – 12:05	Andreas Brunschweiler, Chemically stabilized DNA for DNA-encoded library technology - technology development, library design and screening
12:15-13:15	Neurodegeneration Chairs: Elke Oetjen, Carsten Culmsee	12:15-13:15	Highlight Session II Chairs: Dominique Lunter, Michaela Schulz-Siegmund
12:15 – 12:40	Kristina Friedland, RNA modifications in ageing and Alzheimer disease	12:15 – 12:30	Kerstin Hiesinger, Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase
12:40 – 12:55	Steffen Pockes, Targeting Caspase-2 for the Treatment of Neurodegenerative Diseases	12:30 – 12:45	Frank Karkossa, Oral mixed micelles for solubility enhancement in oral paediatric drug delivery
12:55 – 13:10	Susanne Michels, Effects of the psychiatric risk gene Cacna1c on neuroinflammatory responses in microglia	12:45 – 13:00	Solveigh Koeberle, Redox-dependent regulation of inflammatory lipid mediator biosynthesis by glutathione peroxidases 1 and 2 as promising novel anti-inflammatory strategy
13:10 – 13:15	Discussion	13:00 – 13:15	Christina Lamers, Insight into mode-of-action and structural determinants of the compstatin family of peptidic complement inhibitors

13:25 - 14:10	Poster session 7 (Poster Room D)		Poster session 8 (Poster Room C)
----------------------	--	--	--

14:20 - 15:05	Plenary lecture: Controlling the Fate and Function of Proteins with Photopharmacology Dirk Trauner (Lecture Room 1)
15:05	AWARD SESSION AND CLOSING CEREMONY (Lecture Room 1)